With Novo Nordisk’s blockbuster drugs Wegovy and Ozempic back in stock, copycat versions are no longer allowed – for now.

Novo Nordisk has been busy scaling its manufacturing ... limelight earlier this month with its controversial Super Bowl advert – offers compounded semaglutide. Shares in the company tumbled ...

By comparison, trials pivotal to getting Novo Nordisk's semaglutide — the ingredient ... offering samples for as little as 80p per dose. Adverts list it as a 'weight loss supplement', with ...

We also treat our community members to special offers, promotions, and adverts from us and our partners ... The Independent A spokesperson for Novo Nordisk, the maker of Ozempic, Rybelsus ...

Novo Nordisk has been accepted back into the fold. Two years after suspending Novo, the Association of the British ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ingredient in its weight-loss drugs Ozempic and Wegovy, to lower heart risks.

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...